• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Novo Integrated Sciences Reports 2024 Fiscal Year Financial Results

    12/18/24 4:05:00 PM ET
    $NVOS
    Industrial Machinery/Components
    Industrials
    Get the next $NVOS alert in real time by email

    Novo Integrated Sciences, Inc. (OTC:NVOS) (the "Company" or "Novo"), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints providing services and product innovation, today reported its financial results for the fiscal year ended August 31, 2024.

    Robert Mattacchione, the Company's CEO and Board Chairman, stated, "The Company remains committed to the commercialization of its proprietary product offerings and the expansion and delivery of its essential services and solutions to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and in the future. Specific to increasing the Company's cash position, management continues to focus on raising capital through non-dilutive structures and solutions."

    Financial Information for the Fiscal Year Ended August 31, 2024:

    • As of August 31, 2024, the Company's cash and cash equivalents were $844,584, total assets were $32,141,276, total liabilities were $17,527,351 and total Company stockholders' equity was $14,892,621.
    • Revenues for the year ended August 31, 2024 were $13,294,357, representing an increase of $722,338, or 6%, from $12,572,019 for the same period in 2023. The increase in revenue is principally due to an increase in product sales. Acenzia's and Terragenx's revenue for the year ended August 31, 2024 was $4,713,940 and $122,154, respectively. Revenue from our healthcare services increased by 1%, when comparing the revenue for the year ended August 31, 2024 to the same period in 2023.
    • Operating costs for the year ended August 31, 2024 were $15,818,802, representing an increase of $2,312,925, or 17%, from $13,505,877 for the same period in 2023. The increase in operating costs was principally due to (i) impairment of intangible assets and goodwill being recognized; and (ii) an increase in overhead expenses associated with the operations.
    • Net loss attributed to Novo Integrated Sciences for the year ended August 31, 2024 was $16,166,744, representing an increase of $2,952,192, or 22%, from $13,214,552 for the same period in 2023. The increase in net loss was principally due to (i) impairment of intangible assets and goodwill being recognized; (ii) foreign currency exchange loss arising as a result of intercompany balance reconciliation; and (iii) amortization of debt discount as compared to the previous year.
    • On April 5, 2024, the Company executed a $6.21 million Securities Purchase Agreement and Note (the "Streeterville Note") with Streeterville Capital LLC ("Streeterville"). The Streeterville Note annual interest is 10.9% with a 12-month maturity date and is secured by Acenzia's land/building. This Streeterville Note has no warrants or commitment type shares related to the transaction.
    • On July 8, 2024, the Company filed a registration statement on Form S-1 relating to the resale of up to 3,500,000 shares of the Company's common stock by Streeterville issuable by the Company upon conversion of the Streeterville Note. The prices at which Streeterville may sell the common stock will be determined by the prevailing market price for the shares or in negotiated transactions.
    • On October 8, 2024, Streeterville notified the Company that it would redeem $950,000 of the Streeterville Note. In lieu of payment by the Company to Streeterville of $950,000, the Company and Streeterville agreed to a one-time fee in the amount of $142,500 (representing 15% of the $950,000 redemption amount) payable by the Company to Streeterville. Such amount was added to the outstanding balance under the Streeterville Note. On October 16, 2024, Streeterville submitted a redemption notice in the amount of $142,500. On October 21, 2024, the Company issued 675,724 shares of common stock to Streeterville in payment of the $142,500 redemption amount. Following such issuance, the outstanding balance under the Streeterville Note was $6,579,658.

    About Novo Integrated Sciences, Inc.

    Novo Integrated Sciences, Inc. is pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation. Novo offers an essential and differentiated solution to deliver, or intend to deliver, these services and products through the integration of medical technology, advanced therapeutics, and rehabilitative science.

    We believe that "decentralizing" healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient's home and away from on-site visits to primary medical centers with mass-services. This acceleration of "ease-of-access" in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective healthcare distribution.

    The Company's decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic healthcare delivery to patients and consumers:

    • First Pillar: Service Networks. Deliver multidisciplinary primary care services through (i) an affiliate network of clinic facilities, (ii) small and micro footprint sized clinic facilities primarily located within the footprint of box-store commercial enterprises, (iii) clinic facilities operated through a franchise relationship with the Company, and (iv) corporate operated clinic facilities.
    • Second Pillar: Technology. Develop, deploy, and integrate sophisticated interconnected technology, interfacing the patient to the healthcare practitioner thus expanding the reach and availability of the Company's services, beyond the traditional clinic location, to geographic areas not readily providing advanced, peripheral based healthcare services, including the patient's home.
    • Third Pillar: Products. Develop and distribute effective, personalized health and wellness product solutions allowing for the customization of patient preventative care remedies and ultimately a healthier population. The Company's science-first approach to product innovation further emphasizes our mandate to create and provide over-the-counter preventative and maintenance care solutions.

    Innovation through science combined with the integration of sophisticated, secure technology assures Novo Integrated Sciences of continued cutting edge advancement in patient first platforms.

    For more information concerning Novo Integrated Sciences, please visit www.novointegrated.com. For more information on NHL, please visit www.novohealthnet.com.

    Twitter, LinkedIn, Facebook, Instagram, YouTube

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as "believe," "intend," "expect," "anticipate," "plan," "potential," "continue" or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties are discussed in Novo's filings with the Securities and Exchange Commission. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond Novo's control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Novo's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Novo assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The contents of any website referenced in this press release are not incorporated by reference herein.

     

    NOVO INTEGRATED SCIENCES, INC.

    CONSOLIDATED BALANCE SHEETS

    As of August 31, 2024 and 2023

     

     

     

    August 31,

     

    August 31,

     

     

    2024

     

    2023

    ASSETS

     

     

     

     

     

     

    Current Assets:

     

     

     

     

     

     

    Cash and cash equivalents

     

    $

    844,584

     

     

    $

    416,323

     

    Accounts receivable, net

     

     

    1,916,819

     

     

     

    1,467,028

     

    Inventory, net

     

     

    1,000,742

     

     

     

    1,106,983

     

    Other receivables

     

     

    1,235,423

     

     

     

    1,051,584

     

    Prepaid expenses and other current assets

     

     

    417,282

     

     

     

    346,171

     

    Total current assets

     

     

    5,414,850

     

     

     

    4,388,089

     

     

     

     

     

     

     

     

    Property and equipment, net

     

     

    5,110,776

     

     

     

    5,390,038

     

    Intangible assets, net

     

     

    13,369,868

     

     

     

    16,218,539

     

    Right-of-use assets, net

     

     

    1,691,309

     

     

     

    1,983,898

     

    Goodwill

     

     

    6,554,473

     

     

     

    7,582,483

     

    TOTAL ASSETS

     

    $

    32,141,276

     

     

    $

    35,563,047

     

     

     

     

     

     

     

     

    LIABILITIES AND STOCKHOLDERS' EQUITY

     

     

     

     

     

     

     

     

     

     

     

     

     

    Current Liabilities:

     

     

     

     

     

     

    Accounts payable

     

    $

    3,235,800

     

     

    $

    3,513,842

     

    Accrued expenses

     

     

    1,592,288

     

     

     

    1,233,549

     

    Accrued interest (including amounts to related parties)

     

     

    624,287

     

     

     

    382,666

     

    Government loans and notes payable, current portion

     

     

    45,681

     

     

     

    277,405

     

    Convertible notes payable, net of discount of $3,505,849

     

     

    2,704,151

     

     

     

    558,668

     

    Derivative liability

     

     

    4,685,198

     

     

     

    -

     

    Contingent liability

     

     

    13,836

     

     

     

    61,767

     

    Debentures, related parties, current portion

     

     

    913,598

     

     

     

    916,824

     

    Due to related parties

     

     

    356,928

     

     

     

    533,001

     

    Finance lease liability, current portion

     

     

    4,354

     

     

     

    11,744

     

    Operating lease liability, current portion

     

     

    403,291

     

     

     

    415,392

     

    Total current liabilities

     

     

    14,579,412

     

     

     

    7,904,858

     

     

     

     

     

     

     

     

    Government loans and notes payable, net of current portion

     

     

    112,001

     

     

     

    65,038

     

    Operating lease liability, net of current portion

     

     

    1,440,367

     

     

     

    1,693,577

     

    Deferred tax liability

     

     

    1,395,571

     

     

     

    1,400,499

     

    TOTAL LIABILITIES

     

     

    17,527,351

     

     

     

    11,063,972

     

     

     

     

     

     

     

     

    Commitments and contingencies

     

     

    -

     

     

     

    -

     

     

     

     

     

     

     

     

    STOCKHOLDERS' EQUITY

     

     

     

     

     

     

    Novo Integrated Sciences, Inc.

     

     

     

     

     

     

    Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; Nil shares issued and outstanding at August 31, 2024 and August 31, 2023

     

     

    -

     

     

     

    -

     

    Common stock; $0.001 par value; 499,000,000 shares authorized; 19,054,523 and 15,759,325 shares issued and outstanding at August 31, 2024 and August 31, 2023, respectively

     

     

    19,055

     

     

     

    15,760

     

    Additional paid-in capital

     

     

    96,660,607

     

     

     

    90,973,316

     

    Common stock to be issued (1,700 and 91,138 shares at August 31, 2024 and August 31, 2023)

     

     

    25,500

     

     

     

    1,217,293

     

    Other comprehensive (loss) income

     

     

    1,387,244

     

     

     

    (357,383

    )

    Accumulated deficit

     

     

    (83,199,785

    )

     

     

    (67,033,041

    )

    Total Novo Integrated Sciences, Inc. stockholders' equity

     

     

    14,892,621

     

     

     

    24,815,945

     

    Noncontrolling interest

     

     

    (278,696

    )

     

     

    (316,870

    )

    Total stockholders' equity

     

     

    14,613,925

     

     

     

    24,499,075

     

    TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

     

    $

    32,141,276

     

     

    $

    35,563,047

     

     

    * The consolidated balance sheets' common stock share amounts have been retroactively adjusted to account for the Company's 1:10 reverse stock split, effective November 7, 2023.

    NOVO INTEGRATED SCIENCES, INC.

    CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    For the Years Ended August 31, 2024 and 2023

     

     

     

    Years Ended

     

     

    August 31,

     

    August 31,

     

     

    2024

     

    2023

     

     

     

     

     

    Revenues

     

    $

    13,294,357

     

     

    $

    12,572,019

     

     

     

     

     

     

     

     

    Cost of revenues

     

     

    7,551,853

     

     

     

    7,619,304

     

     

     

     

     

     

     

     

    Gross profit

     

     

    5,742,504

     

     

     

    4,952,715

     

     

     

     

     

     

     

     

    Operating expenses:

     

     

     

     

     

     

    Selling expenses

     

     

    17,137

     

     

     

    15,149

     

    General and administrative expenses

     

     

    14,039,265

     

     

     

    13,490,728

     

    Impairment of assets

     

     

    761,067

     

     

     

    -

     

    Goodwill impairment

     

     

    1,001,333

     

     

     

    -

     

    Total operating expenses

     

     

    15,818,802

     

     

     

    13,505,877

     

     

     

     

     

     

     

     

    Loss from operations

     

     

    (10,076,298

    )

     

     

    (8,553,162

    )

     

     

     

     

     

     

     

    Non-operating income (expense)

     

     

     

     

     

     

    Interest income

     

     

    202,525

     

     

     

    9,027

     

    Interest expense

     

     

    (652,398

    )

     

     

    (360,571

    )

    Other (expense) income

     

     

    (1,032,620

    )

     

     

    607,589

     

    Change in fair value of derivative liability

     

     

    3,594,171

     

     

     

    -

     

    Amortization of debt discount

     

     

    (6,574,862

    )

     

     

    (4,757,121

    )

    Foreign currency transaction losses

     

     

    (1,589,088

    )

     

     

    (215,206

    )

    Total other income (expense)

     

     

    (6,052,272

    )

     

     

    (4,716,282

    )

     

     

     

     

     

     

     

    Loss before income taxes

     

     

    (16,128,570

    )

     

     

    (13,269,444

    )

     

     

     

     

     

     

     

    Income tax expense (recovery)

     

     

    -

     

     

     

    -

     

     

     

     

     

     

     

     

    Net loss

     

    $

    (16,128,570

    )

     

    $

    (13,269,444

    )

     

     

     

     

     

     

     

    Net loss attributed to noncontrolling interest

     

     

    38,174

     

     

     

    (54,892

    )

     

     

     

     

     

     

     

    Net loss attributed to Novo Integrated Sciences, Inc.

     

    $

    (16,166,744

    )

     

    $

    (13,214,552

    )

     

     

     

     

     

     

     

    Comprehensive loss:

     

     

     

     

     

     

    Net loss

     

     

    (16,128,570

    )

     

     

    (13,269,444

    )

    Foreign currency translation loss

     

     

    (1,744,627

    )

     

     

    (922,609

    )

    Comprehensive loss:

     

    $

    (17,873,197

    )

     

    $

    (14,192,053

    )

     

     

     

     

     

     

     

    Weighted average common shares outstanding - basic and diluted

     

     

    18,032,015

     

     

     

    10,165,548

     

     

     

     

     

     

     

     

    Net loss per common share - basic and diluted

     

    $

    (0.89

    )

     

    $

    (1.30

    )

     

    * The consolidated statements of operations and comprehensive loss's share and per share amounts have been retroactively adjusted to account for the Company's 1:10 reverse stock split, effective November 7, 2023.

    NOVO INTEGRATED SCIENCES, INC.

    CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

    For the Years Ended August 31, 2024 and 2023

     

     

    Common Stock

     

    Additional

    Paid-in

     

    Common Stock To

     

    Other Comprehensive

     

    Accumulated

     

    Total Novo Stockholders'

     

    Noncontrolling

     

    Total

     

    Shares

     

    Amount

     

    Capital

     

    Be Issued

     

    Income

     

    Deficit

     

    Equity

     

    Interest

     

    Equity

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Balance, August 31, 2022

     

    3,118,063

     

    $

    3,118

     

    $

    66,084,887

     

     

    $

    9,474,807

     

     

    $

    560,836

     

     

    $

    (53,818,489

    )

     

    $

    22,305,159

     

     

    $

    (257,588

    )

     

    $

    22,047,571

     

    Units issued for cash, net of offering costs

     

    400,000

     

     

    400

     

     

    1,794,600

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    1,795,000

     

     

     

    -

     

     

     

    1,795,000

     

    Cashless exercise of warrants

     

    583,334

     

     

    583

     

     

    1,421,000

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    1,421,583

     

     

     

    -

     

     

     

    1,421,583

     

    Share issuance for convertible debt settlement

     

    10,177,834

     

     

    10,178

     

     

    9,957,962

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    9,968,140

     

     

     

    -

     

     

     

    9,968,140

     

    Exercise of warrants for cash

     

    532,600

     

     

    533

     

     

    532,067

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    532,600

     

     

     

    -

     

     

     

    532,600

     

    Shares issued with convertible notes

     

    265,167

     

     

    265

     

     

    247,622

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    247,887

     

     

     

    -

     

     

     

    247,887

     

    Value of warrants issued with convertible notes

     

    -

     

     

    -

     

     

    257,994

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    257,994

     

     

     

    -

     

     

     

    257,994

     

    Beneficial conversion feature upon issuance on convertible debt

     

    -

     

     

    -

     

     

    164,046

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    164,046

     

     

     

    -

     

     

     

    164,046

     

    Extinguishment of derivative liability due to conversion

     

    -

     

     

    -

     

     

    1,390,380

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    1,390,380

     

     

     

    -

     

     

     

    1,390,380

     

    Common stock for services

     

    358,500

     

     

    359

     

     

    480,233

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    480,592

     

     

     

    -

     

     

     

    480,592

     

    Issuance of common stock to be issued

     

    323,827

     

     

    324

     

     

    8,257,190

     

     

     

    (8,257,514

    )

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

    Fair value of stock options

     

    -

     

     

    -

     

     

    385,335

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    385,335

     

     

     

    -

     

     

     

    385,335

     

    Foreign currency translation loss

     

    -

     

     

    -

     

     

    -

     

     

     

    -

     

     

     

    (918,219

    )

     

     

    -

     

     

     

    (918,219

    )

     

     

    (4,390

    )

     

     

    (922,609

    )

    Net loss

     

    -

     

     

    -

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    (13,214,552

    )

     

     

    (13,214,552

    )

     

     

    (54,892

    )

     

     

    (13,269,444

    )

    Balance, August 31, 2023

     

    15,759,325

     

    $

    15,760

     

    $

    90,973,316

     

     

    $

    1,217,293

     

     

    $

    (357,383

    )

     

    $

    (67,033,041

    )

     

    $

    24,815,945

     

     

    $

    (316,870

    )

     

    $

    24,499,075

     

    Cashless exercise of warrants

     

    245,802

     

     

    246

     

     

    1,323,152

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    1,323,398

     

     

     

    -

     

     

     

    1,323,398

     

    Exercise of warrants for cash

     

    240,400

     

     

    240

     

     

    240,160

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    240,400

     

     

     

    -

     

     

     

    240,400

     

    Shares issued for convertible debt settlement

     

    2,283,176

     

     

    2,283

     

     

    1,608,600

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    1,610,883

     

     

     

    -

     

     

     

    1,610,883

     

    Issuance of common stock to be issued

     

    73,767

     

     

    74

     

     

    1,172,776

     

     

     

    (1,172,850

    )

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

    Common stock issued for services

     

    424,080

     

     

    424

     

     

    1,194,976

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    1,195,400

     

     

     

    -

     

     

     

    1,195,400

     

    Reverse stock split share rounding

     

    27,973

     

     

    28

     

     

    (28

    )

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

    Fair value of stock options

     

    -

     

     

    -

     

     

    147,655

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    147,655

     

     

     

    -

     

     

     

    147,655

     

    Cancellation of agreement

     

    -

     

     

    -

     

     

    -

     

     

     

    (18,943

    )

     

     

    -

     

     

     

    -

     

     

     

    (18,943

    )

     

     

    -

     

     

     

    (18,943

    )

    Foreign currency translation loss

     

    -

     

     

    -

     

     

    -

     

     

     

    -

     

     

     

    1,744,627

     

     

     

    -

     

     

     

    1,744,627

     

     

     

    -

     

     

     

    1,744,627

     

    Net loss

     

    -

     

     

    -

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    (16,166,744

    )

     

     

    (16,166,744

    )

     

     

    38,174

     

     

     

    (16,128,570

    )

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Balance, August 31, 2024

     

    19,054,523

     

    $

    19,055

     

    $

    96,660,607

     

     

    $

    25,500

     

     

    $

    1,387,244

     

     

    $

    (83,199,785

    )

     

    $

    14,892,621

     

     

    $

    (278,696

    )

     

    $

    14,613,925

     

     

    * The consolidated statements of stockholder's equity share amounts have been retroactively adjusted to account for the Company's 1:10 reverse stock split, effective November 7, 2023.

    NOVO INTEGRATED SCIENCES, INC.

    CONSOLIDATED STATEMENTS OF CASH FLOWS

    For the Years Ended August 31, 2024 and 2023

     

     

     

     

     

     

     

    Years Ended

     

     

    August 31,

     

    August 31,

     

     

    2024

     

    2023

     

     

     

     

     

    CASH FLOWS FROM OPERATING ACTIVITIES:

     

     

     

     

     

     

    Net loss

     

    $

    (16,128,570

    )

     

    $

    (13,269,444

    )

    Adjustments to reconcile net loss to net cash used in operating activities:

     

     

     

     

     

     

    Depreciation and amortization

     

     

    2,261,519

     

     

     

    2,302,754

     

    Fair value of vested stock options

     

     

    147,656

     

     

     

    385,335

     

    Financing costs for debt extension

     

     

    -

     

     

     

    1,421,583

     

    Change in fair value of derivative liability

     

     

    (3,594,171

    )

     

     

    -

     

    Default payment and interest paid through common share issuance

     

     

    -

     

     

     

    205,349

     

    Cashless exercise of warrants

     

     

    1,323,398

     

     

     

    -

     

    Common stock issued for services

     

     

    1,195,400

     

     

     

    480,592

     

    Operating lease expense

     

     

    616,799

     

     

     

    797,515

     

    Cancellation of shares to be issued

     

     

    62,130

     

     

     

    -

     

    Amortization of debt discount

     

     

    6,574,862

     

     

     

    4,757,121

     

    Foreign currency transaction losses

     

     

    1,589,088

     

     

     

    215,206

     

    Impairment of assets

     

     

    761,067

     

     

     

    -

     

    Assets write off

     

     

    321,872

     

     

     

    -

     

    Goodwill impairment

     

     

    1,001,333

     

     

     

    -

     

    Changes in operating assets and liabilities:

     

     

     

     

     

     

    Accounts receivable

     

     

    (453,252

    )

     

     

    (597,191

    )

    Inventory

     

     

    (210,883

    )

     

     

    (255,781

    )

    Prepaid expenses and other current assets

     

     

    (259,972

    )

     

     

    210,382

     

    Accounts payable

     

     

    (267,211

    )

     

     

    1,770,589

     

    Accrued expenses

     

     

    330,276

     

     

     

    153,598

     

    Accrued interest

     

     

    275,618

     

     

     

    (58,066

    )

    Operating lease liability

     

     

    (616,799

    )

     

     

    (762,852

    )

    Net cash used in operating activities

     

     

    (5,069,840

    )

     

     

    (2,243,315

    )

     

     

     

     

     

     

     

    CASH FLOWS FROM INVESTING ACTIVITIES:

     

     

     

     

     

     

    Purchase of property and equipment

     

     

    (5,034

    )

     

     

    (49,224

    )

     

     

     

     

     

     

     

    Net cash (used in) provided by investing activities

     

     

    (5,034

    )

     

     

    (49,224

    )

     

     

     

     

     

     

     

    CASH FLOWS FROM FINANCING ACTIVITIES:

     

     

     

     

     

     

    (Repayments to) receipt from related parties

     

     

    (396,418

    )

     

     

    7,206

     

    Proceeds from notes payable

     

     

    402

     

     

     

    222,780

     

    Repayments of notes payable

     

     

    (183,725

    )

     

     

    (37,130

    )

    Repayments of finance leases

     

     

    (7,334

    )

     

     

    (8,611

    )

    Proceeds from issuance of convertible notes

     

     

    8,649,153

     

     

     

    1,285,903

     

    Repayment of convertible notes

     

     

    (3,311,536

    )

     

     

    (3,033,888

    )

    Proceeds from the sale of common stock, net of offering costs

     

     

    -

     

     

     

    1,795,000

     

    Proceeds from exercise of warrants

     

     

    240,400

     

     

     

    532,600

     

    Net cash provided by financing activities

     

     

    4,990,942

     

     

     

    763,860

     

     

     

     

     

     

     

     

    Effect of exchange rate changes on cash and cash equivalents

     

     

    512,193

     

     

     

    (233,685

    )

     

     

     

     

     

     

     

    NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

     

     

    428,261

     

     

     

    (1,762,364

    )

     

     

     

     

     

     

     

    CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR

     

     

    416,323

     

     

     

    2,178,687

     

     

     

     

     

     

     

     

    CASH AND CASH EQUIVALENTS, END OF YEAR

     

    $

    844,584

     

     

    $

    416,323

     

     

     

     

     

     

     

     

    CASH PAID FOR:

     

     

     

     

     

     

    Interest

     

    $

    190,491

     

     

    $

    432,094

     

    Income taxes

     

    $

    -

     

     

    $

    -

     

     

     

     

     

     

     

     

    SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:

     

     

     

     

     

     

    Common stock issued for convertible debt

     

    $

    1,610,883

     

     

    $

    9,968,140

     

    Common stock issued for acquisition

     

    $

    -

     

     

    $

    -

     

    Warrants issued with convertible notes

     

    $

    -

     

     

    $

    257,994

     

    Beneficial conversion feature upon issuance of convertible notes

     

    $

    -

     

     

    $

    164,046

     

    Debt discount recognized on derivative liability

     

    $

    -

     

     

    $

    1,390,380

     

    Extinguishment of derivative liability due to conversion

     

    $

    -

     

     

    $

    1,390,380

     

    Debt discount recognized on convertible note

     

    $

    -

     

     

    $

    975,024

     

    Common stock issued with convertible notes

     

    $

    -

     

     

    $

    247,887

     

    Common stock issued for services

     

    $

    1,195,400

     

     

    $

    -

     

    Cashless exercise of warrants

     

    $

    1,323,398

     

     

    $

    -

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241218007774/en/

    Get the next $NVOS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NVOS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NVOS
    SEC Filings

    See more
    • SEC Form SEC STAFF ACTION filed by Novo Integrated Sciences Inc.

      SEC STAFF ACTION - Novo Integrated Sciences, Inc. (0001138978) (Filer)

      5/20/25 9:00:03 AM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • Novo Integrated Sciences Inc. filed SEC Form 8-K: Leadership Update

      8-K - Novo Integrated Sciences, Inc. (0001138978) (Filer)

      5/6/25 4:30:35 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • Novo Integrated Sciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Novo Integrated Sciences, Inc. (0001138978) (Filer)

      5/2/25 4:13:03 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials

    $NVOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Operating Officer David Christopher Mehlin

      4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)

      9/12/24 6:05:09 AM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • SEC Form 4 filed by David Christopher Mehlin

      4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)

      6/2/23 4:05:37 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • SEC Form 4 filed by Novo Integrated Sciences Inc.

      4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)

      8/10/22 1:01:17 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials

    $NVOS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Novo Integrated Sciences Reports 2024 Fiscal Year Financial Results

      Novo Integrated Sciences, Inc. (OTC:NVOS) (the "Company" or "Novo"), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints providing services and product innovation, today reported its financial results for the fiscal year ended August 31, 2024. Robert Mattacchione, the Company's CEO and Board Chairman, stated, "The Company remains committed to the commercialization of its proprietary product offerings and the expansion and delivery of its essential services and solutions to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and

      12/18/24 4:05:00 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • Novo Integrated Sciences Reports Fiscal Year 2024 Third Quarter Financial Results

      Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo"), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the third fiscal quarter ended May 31, 2024. Robert Mattacchione, Novo's CEO and Board Chairman, stated, "The Company's fiscal year 2024 third quarter emphasized maximizing operational efficiencies for all business units. The Company continues to work with certain prospective financial partners to close previously announced non-traditional financing opportunities to raise foundation

      7/19/24 5:00:00 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • Novo Integrated Sciences Receives Commencement of Disbursement Notice for SBLC Leasing and Monetizing Program

      Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announced today that it has received notice of the commencement of disbursement for the complete monetization of a Standby Letter of Credit ("SBLC"). The initial disbursement represents the first payment as per the arrangement creating a release of lien resulting in the subsequent final advance to the Company. With this initial disbursement the Company expects final distribution to follow on or before August 2. As previously reported, the Company entered into an application for the monetizing program whereby the Company is projected to receive gross funding proceeds of approximately $78 million under the SBLC monetizatio

      7/18/24 4:05:00 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials

    $NVOS
    Leadership Updates

    Live Leadership Updates

    See more
    • Novo Integrated Sciences Appoints New President

      Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announces today Mr. Robert Oliva has been appointed as the Company's new President. Mr. Oliva succeeds Mr. Christopher David, who remains as the Company's Chief Operating Officer and as a member of the Company's Board of Directors. Mr. Oliva has over 35 years of ownership and proven business development with expertise in manufacturing related operations. Mr. Oliva is expected to advance the Company's product-related operational efficiency while managing aggressive, yet sustainable growth and improving margins. Robert Mattacchione, the Company's CEO and Board Chairman, stated, "The addition of Mr. Oliva comes at a tim

      2/16/24 2:00:00 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • Novo Integrated Sciences Appoints Dr. Indrajit (Indra) Sinha Ph.D. as Chief Science Officer

      Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announces that Dr. Indrajit "Indra" Sinha, Ph.D. has been appointed as Novo's Chief Science Officer, effective June 24, 2021. Dr. Sinha brings over 25 years of experience in various areas of cross-disciplinary translational research, drug development, biotechnology, technology transfer, and biopharmaceutical compliance. His work has been extensively published in highly reputed peer reviewed journals. Through his passion for utilizing under-appreciated technologies and applying them in innovative ways to achieve previously unattainable outcomes, he has created various intellectual property and patents. Robert Mattacchio

      7/7/21 8:00:00 AM ET
      $NVOS
      Industrial Machinery/Components
      Industrials

    $NVOS
    Financials

    Live finance-specific insights

    See more
    • Novo Integrated Sciences Completes Acquisition of Clinical Consultants International LLC

      Dr. Joseph M. Chalil, MD, MBA, FACHE Appointed Chief Medical Officer and the New President of Novomerica Health Group Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo"), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation, today announced the Company has completed the acquisition of Clinical Consultants International LLC ("CCI"), a global consulting firm, based in Boca Raton, Florida, specializing in providing value-added services for the pharmaceutical, biotech, healthcare management, hospital management, medical marketing and strategic planning, health policy, and medic

      4/7/22 8:00:00 AM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • Novo Integrated Sciences Acquires Majority Stake in Terragenx and Intellectual Property for FDA and Health Canada Approved Water-Soluble Iodine Micro-Nutrient

      Iodine, an essential nutrient, when in aerosolized aqueous form can be safely ingested to kill bacteria and deactivate various viruses Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo"), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation, announced today it has acquired 91% of Terragenx and the intellectual property portfolio for the unique formulation and manufacturing capability to produce a water-soluble iodine micro-nutrient that is FDA and Health Canada approved for over-the-counter and e-commerce distribution (the "Iodine IP and Patents"). Iodine is a naturally oc

      11/30/21 8:00:00 AM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • Novo Integrated Sciences and Novo Healthnet Limited Complete Acquisition of Acenzia

      Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announced today Novo Healthnet Limited, a wholly owned subsidiary of the Company ("NHL"), completed the acquisition of Acenzia Inc., a Windsor Canada based company that provides nutraceutical health solutions through advanced bio-science research and development, proprietary manufacturing, and personalized diagnostics. The all-share transaction, which closed on June 24, 2021, is valued at $14,884,039, or $3.91 per share, and is subject to purchase price adjustment within 90 days of the closing date pending completion of an audit and working capital requirement provisions. Robert Mattacchione, Novo's Chairman and CEO, st

      6/29/21 8:00:00 AM ET
      $NVOS
      Industrial Machinery/Components
      Industrials

    $NVOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Novo Integrated Sciences Inc. (Amendment)

      SC 13G/A - Novo Integrated Sciences, Inc. (0001138978) (Subject)

      2/6/24 12:00:24 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13G/A filed by Novo Integrated Sciences Inc. (Amendment)

      SC 13G/A - Novo Integrated Sciences, Inc. (0001138978) (Subject)

      2/10/23 3:45:24 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13G filed by Novo Integrated Sciences Inc.

      SC 13G - Novo Integrated Sciences, Inc. (0001138978) (Subject)

      2/8/22 4:28:22 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials